Arbutus Biopharm (ABUS) Stock News

Summary not available.

Arbutus (Nasdaq: ABUS) reported Q4 and full-year 2025 results and a corporate update on March 23, 2026. Key highlights include $91.5M in cash and marketable securities, a $2.25B global settlement with Moderna (noncontingent $950M plus $1.3B contingent), and two additional imdusiran patients achieving functional cure, totaling 10 to date.

2025 revenue was $14.1M, net loss $33.5M, and 192.5M shares outstanding. The company plans to evaluate a return of capital in Q3 2026 following receipt of settlement proceeds.

Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences announced a $2.25 billion global settlement with Moderna on March 3, 2026. Moderna will pay $950 million upfront in July 2026 and a $1.3 billion contingent payment tied to an appellate ruling on Section 1498. The settlement includes a court judgment of infringement and no invalidity on four patents and grants Moderna a global non-exclusive license to LNP delivery technology for infectious-disease mRNA vaccines.

Arbutus is evaluating a return of capital to shareholders in Q3 2026 in conjunction with the upfront payment.

Arbutus (NASDAQ: ABUS) reported Q3 2025 results and a corporate update on Nov 13, 2025. Key financials include $93.7M in cash, cash equivalents and marketable securities as of Sept 30, 2025, down from $122.6M at Dec 31, 2024, and a Q3 net loss of $7.7M ($0.04 per share) versus $19.7M a year earlier. Total revenue was $0.5M for the quarter.

Clinical highlights for imdusiran (AB-729): 46% of Phase 2a patients discontinued all treatment; 94% of long-term follow-up patients remain off all treatment up to 2+ years; 100% of Phase 1b HBV DNA+ patients reached levels below quantification by week 18. Moderna U.S. jury trial scheduled March 2026; favorable claim construction ruling in Pfizer-BioNTech suit issued Sept 2025.

Arbutus (Nasdaq: ABUS) announced four abstracts accepted for poster presentation at AASLD The Liver Meeting® 2025 (Nov 7–11, 2025) highlighting clinical data for imdusiran (AB-729) and oral PD-L1 inhibitor AB-101. Three imdusiran abstracts report safety/tolerability at 60 mg and 90 mg q8w through 24–48 weeks, genotype B/C enrichment among IFN responders in IM-PROVE I, and on-treatment increases in soluble immune biomarkers linked to HBsAg loss and NA discontinuation criteria (baseline HBsAg ≤1000 IU/mL). The AB-101 poster (Poster of Distinction) reports generally favorable tolerability up to 30 mg QD for 28 days and ~83% mean maximal PD-L1 receptor occupancy at 30 mg. Poster materials available Nov 7, 2025; full abstracts published in Hepatology October supplement.

Arbutus Biopharma (Nasdaq: ABUS) reported Q2 2025 financial results, posting a net income of $2.5 million ($0.01 per share) compared to a loss of $19.8 million in Q2 2024. Total revenue reached $10.7 million, up from $1.7 million year-over-year, primarily due to recognizing deferred revenue after reacquiring Greater China rights to imdusiran.

The company maintained a strong financial position with $98.1 million in cash and equivalents. Operating expenses decreased significantly, with R&D expenses falling to $5.5 million from $15.6 million, and G&A expenses dropping to $3.3 million from $7.5 million, reflecting the company's streamlining efforts.

Key corporate updates include Dr. Harry Janssen joining the Scientific Advisory Board, Dr. Roger Sawhney joining the Board of Directors, and ongoing LNP patent litigation against Moderna and Pfizer/BioNTech, with trials expected in 2026.

Arbutus Biopharma (Nasdaq: ABUS) has announced two significant developments: the reacquisition of Greater China rights to imdusiran from Qilu Pharmaceutical and the formation of a new Scientific Advisory Board focused on late-stage clinical trials.

The company has reported that imdusiran has achieved functional cure in 8 patients across Phase 2a clinical trials (IM-PROVE I and II) when used in combination therapy. Notably, two patients achieved cure without interferon, and seven had baseline HBsAg levels below 1000 IU/mL.

The newly formed Scientific Advisory Board includes five globally recognized leaders in chronic hepatitis B virus (cHBV) treatment: Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski, and Man-Fung Yuen. These experts will advise Arbutus on its cHBV pipeline strategic evaluation.

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 2025 financial results and provided key updates. The company announced that imdusiran combination therapy has achieved functional cure in 8 chronic hepatitis B (cHBV) patients, including 2 patients who received no interferon. Their oral PD-L1 inhibitor, AB-101, demonstrated 100% receptor occupancy in 11 of 13 evaluable healthy volunteers at the 40mg dose, with no serious adverse events reported. The company ended Q1 2025 with $112.7 million in cash and investments, down from $122.6 million in Q4 2024. Revenue was $1.8 million, up from $1.5 million in Q1 2024. Net loss widened to $24.5 million ($0.13 per share) compared to $17.9 million ($0.10 per share) in Q1 2024. The company also appointed Andrew J. Sung as General Counsel, bringing over $28 billion in life sciences deal experience.

Arbutus Biopharma (NASDAQ: ABUS) presented significant clinical trial data for its HBV assets at EASL Congress 2025. The Phase 2a trial of imdusiran combined with VTP-300 and low-dose nivolumab showed promising results, with 15.3% functional cure rate in Group C. Three patients achieved HBsAg loss and seroconversion, all with baseline HBsAg <1000 IU/mL. The treatment combination was well-tolerated with no serious adverse events. Additionally, data from AB-101's Phase 1a/1b trial demonstrated that the oral PD-L1 inhibitor was safe and well-tolerated at 10mg daily dosing, showing high receptor occupancy in chronic hepatitis B patients with no liver dysfunction.